H2020-SFS: SPRINT

Project: Sustainable Plant Protection Transition: a global health approach

Funding: H2020 MSCA Sustainable Security, 2020-2025

Coordinator: Prof. Violette Geissen (Wageningen University, The Netherlands)

Beneficiaries: 28 beneficiaries among which UAntwerp (Benjamin Vervaet, Patrick D'Haese, Pathophysiology)

FWO research project COVID call 2: Mucine isoform micobiome interactions in COVID-19 infection

Project: Mucine isoform-microbiome interactions determing the severity of a COVID-19 infection: useful for patient stratification?

Funding: FWO Covid-19 call 2

PIs: Benedicte De Winter (LEMP), Annemieke Smet (LEMP), Kevin Ariën (ITM); Aline Verstraeten (GENCOR), Surbhi Malhotra, Koen Vercauteren

H2020 WIDEPSREAD: SPRINGBOARD: development of antibacterials


Project: SPRINGBOARD for excellence in advanced development of antibacterials

Funding: H2020 Widespread, 2020-2023

Coordinator: Prof. RAIVIS ZALUBOVSKIS (Latvian Institute for Organic Synthesis, Riga, Latvia)

Beneficiaries: UAntwerp (Paul Cos, Koen Augustyns), University of Firenze, University of Copenhagen, University of Helsinki

Innovative Medicine Initiative: RespiriTB

Project: Advancing a portfolio of novel compounds with the potential to treat TB to address AMR. Progress new assets (one pre New Molecular Entity (preNME) and one first-time-in-human (FTIH) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Funding: IMI (European Union and EFPIA)

More info: https://www.studio98.nl/Projects/tmp/respiritb/V4/index.html

Principal investigators for University of Antwerp:

LMPH: Prof. Paul Cos, Dr. Davie Cappoen, Prof. Yann Sterckx, Prof Peter Delputte 

UAMC: Prof. Koen Augustyns, Prof. Pieter Van der Veken, Prof. Hans De Winter

ORSY: Prof. Bert Maes

Other principal investigators: Janssen Pharmaceutica, Leiden University Medical Center, Sorbonne University, Medical University of Vienna, University of Copehnagen, Mitologics (SME), FFUND (SME) 

Innovative Medicine Initiative: RespiriNTM

Project: Advancing a portfolio of novel compounds with the potential to treat NTM to address AMRProgress novel assets (One first-time-in-human (FTIH)) for non-tuberculosis mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs

Funding: IMI (European Union and EFPIA)

More info: https://www.studio98.nl/Projects/tmp/respiritb/V4/index.html

Principal investigators for University of Antwerp:

UAMC: Prof. Koen Augustyns, Prof. Pieter Van der Veken, Prof. Hans De Winter

ORSY: Prof. Bert Maes

Other principal investigators: Janssen Pharmaceutica, Leiden University Medical Center, Sorbonne University, Medical University of Vienna, University of Copehnagen, Mitologics (SME), FFUND (SME) 

MSCA-H2020-ETN INSPIRE: safety pharmacolgy with focus on cardiotoxicity

Project: INSPIRE aims to extend the SP toolbox by exploring novel technologies and by turning these into new products or services for improved assessment of drug-induced CV toxicity.For more details, please visit: https://www.uantwerpen.be/en/projects/inspire-safety-pharmacology/research/

Funding: H2020 MSCA European Training Network, 2020-2023

Coordinator: Prof. Pieter-Jan Guns (PHYSPHAR, UAntwerp)

Beneficiaries:UAntwerp (coordinator), Maastricht University, University of Nottingham, INRIA (the French National Institute for Computer Science and Applied Mathematics),Weismann Institute of Science (Israel), Ncardia, UCB; Notocord, TSE Systems, Boehringer-Ingelheim

Equipment: Mosquito Xtal3 crystallization robot

The Mosquito Xtal3 is a state-of-the-art crystallization robot that has become an indispensable workhorse in any structural biology laboratory. The Mosquito Xtal3 allows fast, robust and high-throughput crystallization of biological macromolecules, which is a basic requirement for structure determination through macromolecular X-ray crystallography.

PIs: Prof. dr. I. De Meester (FAR/LMB); Prof. dr. ir. Y. Sterckx (FAR/LMB); Prof. dr. X. Van Ostade (BMW/PPES); Prof. dr. H. De Winter (FAR/UAMC); dr. D. Cappoen (BMW/LMPH)

In case of interest: please contact yann.sterckx@uantwerpen.be

Proof of Concept Project (IOF-POC)

Project: ADME studies of lead ferroptosis inhibitor which blocks organ injury and neurodegeneration in mice

Funding: IOF

PIs: Tom Vanden Berghe, Koen Augustyns, Alexander van Nuijs

Equipment: Cell Death Platform

Cell Death Platform to measure cell death along any other biochemical parameter that is crucial to determine the mode of cell death such as caspase activation, reactive oxygen species, calcium, mitochondrial membrane potential, lysosomal leakage and lipid peroxidation:

In case of interest: contact Tom Vanden Berghe (tom.vandenberghe@uantwerpen.be)

H2020-RIA: L-EU-CO: visceral leishmaniasis combination therapies

Project: From laboratory to patients: Moving new compounds through Phase I for the development of novel visceral leishmaniasis (VL) combination treatments

Funding:H2020-SC1-BHC-2018-2020: Better Health and care, economic growth and sustainable health systems.

Participants:

1 (Coordinator) Drugs for Neglected Diseases initiative DNDi Switzerland

2 Accelera ACC Italy

3 Diomune DIO Spain

4 GalChimia GAL Spain

5 GlaxoSmithKline GSK Spain

6 The Institute of Endemic Diseases IEND Sudan

7 Swiss Tropical and Public Health Institute SwissTPH Switzerland

8 University of Antwerp UA Belgium (LMPH: Prof. Louis Maes, Prof. Guy Caljon)

9 University of Dundee UNIVDUN United Kingdom

10 University of Gondar UOG Ethiopia

 

Neuregulin-1 as a therapy for atrial fibrillation and the role of the NRG-1/ErbB4 system in atrial remodelling (Concerted Research Action)

Project: We hypothesize that the endothelium-derived NRG-1 – ErbB4 system is activated in atrial tissue of patients with atrial fibrillation.If successful, this project could open new avenues for treatment of atrial fibrillation by addressing atrial tissue remodeling.

Funding: BOF (University Research Fund)

PI: Hein Heidbuchel (Cardiology)

co-PI: Gilles De Keulenaer, Guido De Meyer (both Physiopharmacology)

 

 

Proof of Concept project (IOF)

Project: Drug delivery systems and in vivo efficacy of the serine protease inhibitor UAMC-00050 in a preclinical model for Irritable Bowel Syndrome

Funding: IOF

Principal investigator: Benedicte De Winter (LEMP)

co-PIs: Koen Augustyns (UAMC), Filip Kiekens

ERA.Net RUS Plus: ErbB4 agonists

Project: We propose a multi-disciplinary approach to identify novel potent and selective agonists of the ErbB4 receptor, to test these in validated rodent models of chronic heart failure, and to define specific patient populations in the heterogeneous field of cardiovascular diseases that could benefit from ErbB4 agonists.

Funding: FWO (Flanders-Belgium),  SNSF (Switserland), RFBR (Russian Foundation for Basic Research)

Principal investigator: Prof. Gilles De Keulenaer (Physiopharmacology lab, University of Antwerp, Belgium)

Co-principal investigators: Prof. Vincent Segers (Physiopharmacology lab, University of Antwerp, Belgium), Prof. Marijke Brink (University of Basel, Switserland),  Prof. Yuri Belenkov (University of Sechenov, Moscow, Russia)

Equipment: Interferometry-based biosensor (FWO-Medium Scale Research Infrastructure)

Project: Physical and functional interactions between biomolecules play pivotal roles in all aspects of human health and disease.  Biomedically important enzymes, such as proteases and kinases, despite regulating nearly every biological function, remain a relatively underdeveloped drug target group.  This new biomolecular interactions platform will aid with the search for new  enzyme-based drug targets for diseases such as cancer, metabolic disorders and neurodegenerative disorders.

Funding: FWO-Medium Scale Research Infrastructure 

PI: I. De Meester

co-PIs: A. Lambeir, H. De Winter, P. Van der Veken, S. Maudsley, S. Dewilde, X. Van Ostade, W. Vanden Berghe, P. Delputte, F. Kooy, K. De Wael

Equipment: Comprehensive Liquid Chromatography - Ion Mobility - Quadrupole-Time-of-Flight Mass Spectrometry for innovative metabolomics (FWO-Medium Scale Research Infrastructure)

Project: Metabolomics is the study of the unique chemical fingerprints that specific cellular processes leave behind. The metabolome is the collection of all metabolites in a biological cell, tissue, organ or organism, which are the end products of cellular processes.  Metabolomics can be used to investigate diseases, drug responses and pollutants in our environment.

Funding: FWO-Medium Scale Research Infrastructure 

PI: A. Covaci

co-PIs: L. Maes, K. Augustyns, G. De Meyer, N. Hermans, G. Baggerman, F. Lemière, K. Laukens, L. Bervoets, I. De Meester, A. Van Nuijs.

FWO-EOS: Molecular mechanisms of cellular DEath and Life decisions in Inflammation, Degeneration and Infection (MODEL-IDI)

Project: The research program on MOlecular mechanisms of cellular DEath and Life decisions in Inflammation, Degeneration and Infection (MODEL-IDI) aims at performing fundamental research on the biology of cell death modalities, cell survival regulation and their consequences on the onset/progression of diseases

Funding: FWO Excellence of Science (FWO-EOS)

Principal investigator: Peter Vandenabeele (VIB-UGhent)

Co-principal investigators: Mathieu Bertrand (VIB-UGhent), Tom Vanden Berghe (VIB-UGhent), Koen Augustyns (UAntwerp), Wim Martinet (UAntwerp), Emmanuel Dejardin, Isabelle Manfroid (Université de Liège), Alessandra Cardozo (Université Libre de Bruxelles), Mathias Heikenwälder (Deutsches Krebsforschungszentrum - Heidelberg), Raffaella Gozzelino (Universidade Nova de Lisboa)  

H2020-MSCA-ITN: Integrated Training in Dry Eye disease Drug Development (IT-DED³)

Project: The European network for Integrated Training in Dry Eye Disease Drug Development (IT-DED3) aims to deliver multidisciplinary and entrepreneurial researchers trained to develop new therapies for patients suffering from dry eye diseases (DED). For more details, please visit: www.itded3.eu

Funding: H2020 MSCA European Training Network

Coordinator: Prof. Koen Augustyns (UAMC, UAntwerp)

Beneficiaries: Prof. Paul Cos (LMPH, UAntwerp), Prof. Christophe Baudoin (Vision Institute, Paris), Dr. Philipp Steven (University Hospital Cologne), Prof. Margarita Calonge (University of Valladolid, Spain), Prof. Osvalds Pucovics (Latvian Institute of Organic Synthesis), Prof. Arto Urtti (University of Eastern Finland), Dr. Ana Matias (iBET)

https://www.uantwerpen.be/en/projects/dry-eye-disease-drug-development/

H2020-MSCA-IF: ONCOPHAGY

Project: Novel Atg4B inhibitors and dual [Atg4B-carbonic anhydrase] inhibitors for interfering with cytoprotective mechanisms of cancer cells in the acidic tumor micro-environment.

Funding: H2020 MSCA Individual Fellowship 2017-2018

Researcher: Dr. Muhammet Tanç

Promotor: Prof. Pieter Van der Veken

Co-promotors: Prof. Wim Martinet, Prof. Marc Peeters (CORE)

 

Arterial stiffening as a common pathophysiological mechanism in cardiac and kidney failure and brain degeneration (BOF: Concerted Research Action)

Project: this project aims to unravel the molecular processes involved in arterial stiffness that might lead to prevention and/or treatment of arterial stiffness and hence reduce the risk and severity of age-related heart and kidney damage and brain degeneration.

Funding: BOF-GOA (Concerted Research Action)

Researchers: Guido De Meyer (promotor, Physiopharmacology), Patrick D'Haese (co-promotor, Pathophysiology), Stuart Maudsley (Translational Neurobiology Group VIB)

FWO-SBO: TRP sensation: treatment of visceral hypersensitivity

Project: TRP channel sensitization as target for treatment of hypersensitivity

Funding: FWO-SBO project

Researchers:

Principal investigator: Guy Boeckxstaens (KUL, Gastro-TARGID)

Co-principal investigators:

UAntwerp: Benedicte De Winter (LEMP), Koen Augustyns (Medicinal Chemistry), Ingrid De Meester and Anne-Marie Lambeir (Medical Biochemistry)

KUL: Mira Wouters (Gastro-TARGID), Deirdre Cabooter (Pharmacy), Patrick Augustijns (Pharmacy), Paul Declerck (PharmAbs)

 

 

 

High-Frequency Ultrasound Imaging System Vevo 2100 (Hercules Foundation)

Project: This project represents a formal research agreement between UA and on the other hand the Hercules Foundation. UA provides the Hercules Foundation research results mentioned in the title of the project under the conditions as stipulated in this contract.

Funding: Hercules Foundation

Researchers:

Principal investigator: De Meyer Guido (Physiopharmacology)

Co-principal investigators: Claeys Marc (Cardiovascular Diseases), De Keulenaer Gilles (Physiopharmacology), D'Haese Patrick (Pathophysiology), Loeys Bart (Medical Genetics), Vrints Christiaan (Translational Pathophysiological Research (TPR) - Cardiovascular Diseases)

Equipment for high-speed refrigerated, preparative ultracentrifugation, automated gradient formation and fraction collection and analysis (Hercules Foundation)

Project: This project represents a formal research agreement between UA and on the other hand the Hercules Foundation. UA provides the Hercules Foundation research results mentioned in the title of the project under the conditions as stipulated in this contract.

Funding: Hercules foundation

Researchers:

Principal investigator: Maes Louis (LMPH)

Co-principal investigators: De Meyer Guido (Physiopharmacology), Delputte Peter (LMPH), Kumar-Singh Samir (Laboratory of Cell Biology & Histology), Lambeir Anne-Marie (Medical Biochemistry), De Meester Ingrid (Medical Biochemistry), Dewilde Sylvia, Lebeer Sarah, Leroy Jo, Van Cruchten Steven, Wenseleers Wim